FibroGen – Late-Breaking Roxadustat Safety Results at Kidney Week 2020
Dr. Lynda Szczech, VP of Clinical Development and Medical Affairs at FibroGen discusses new data presented at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined on roxadustat, the company’s investigational first-in-class oral treatment for anemia in patients with chronic kidney disease (CKD). These data will build upon roxadustat’s well-defined efficacy and safety profile. If approved in December 2020, roxadustat will be the first new anemia treatment option for CKD patients in about 30 years. Its oral formulation could make anemia management more convenient for patients and limit time spent in transfusion facilities, an especially important consideration during flu season and the COVID-19 pandemic.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on COVID. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in COVID and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about COVID?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Lynda Szczech is Vice President of Clinical Development and Medical Affairs at FibroGen. As a nephrologist with over 25 years of clinical and research experience, she has more than 160 peer-reviewed publications, having studied many of the issues involved with anemia and cardiovascular disease, as well as complications of chronic kidney disease (CKD) and issues with public policy and decision making related to end stage kidney disease (ESKD). In addition to serving on the ASN’s Public Policy Board as well as Communications Committee, Dr. Szczech was the Chair of the Dialysis Advisory Group for the ASN as well as the President of the National Kidney Foundation.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
